Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Evaluation of the impact of fetal fibronectin test implementation on hospital admissions for preterm labour in Ontario: a multiple baseline time-series design.

Fell DB, Sprague AE, Grimshaw JM, Yasseen AS 3rd, Coyle D, Dunn SI, Perkins SL, Peterson WE, Johnson M, Bunting PS, Walker MC.

BJOG. 2014 Mar;121(4):438-46. doi: 10.1111/1471-0528.12511. Epub 2013 Dec 2.

2.

Self-monitoring of blood glucose in patients with diabetes who do not use insulin--are guidelines evidence-based?

Aakre KM, Watine J, Bunting PS, Sandberg S, Oosterhuis WP.

Diabet Med. 2012 Oct;29(10):1226-36. doi: 10.1111/j.1464-5491.2012.03659.x. Review.

PMID:
22435892
4.

Comparison of the anti-cyclic citrullinated peptide and rheumatoid factor in rheumatoid arthritis at an arthritis center.

Attar SM, Bunting PS, Smith CD, Karsh J.

Saudi Med J. 2009 Mar;30(3):446-7. No abstract available.

PMID:
19271083
5.

Reliability of self-report versus chart-based prostate cancer, PSA, DRE and urinary symptoms.

Sayre EC, Bunting PS, Kopec JA.

Can J Urol. 2009 Feb;16(1):4463-71.

PMID:
19222884
6.

Do guidelines for the diagnosis and monitoring of diabetes mellitus fulfill the criteria of evidence-based guideline development?

Nagy E, Watine J, Bunting PS, Onody R, Oosterhuis WP, Rogic D, Sandberg S, Boda K, Horvath AR; IFCC Task Force on the Global Campaign for Diabetes Mellitus.

Clin Chem. 2008 Nov;54(11):1872-82. doi: 10.1373/clinchem.2008.109082. Epub 2008 Sep 4.

7.

Mass colorectal cancer screening: methodological quality of practice guidelines is not related to their content validity.

Watine JC, Bunting PS.

Clin Biochem. 2008 May;41(7-8):459-66. doi: 10.1016/j.clinbiochem.2007.12.020. Epub 2008 Jan 11.

PMID:
18226597
8.

[Mass screening for colorectal cancer with the guaiac fecal occult blood test: possible population benefits, proven individual risks].

Watine JC, Bunting PS.

Presse Med. 2008 Feb;37(2 Pt 2):363-6. Epub 2007 Dec 21. French. No abstract available.

PMID:
18096357
9.

Conflict between guideline methodologic quality and recommendation validity: a potential problem for practitioners.

Watine J, Friedberg B, Nagy E, Onody R, Oosterhuis W, Bunting PS, Charet JC, Horvath AR.

Clin Chem. 2006 Jan;52(1):65-72. Review.

10.

Reliability of point-of-care testing for glucose measurement in critically ill adults.

Kanji S, Buffie J, Hutton B, Bunting PS, Singh A, McDonald K, Fergusson D, McIntyre LA, Hebert PC.

Crit Care Med. 2005 Dec;33(12):2778-85.

PMID:
16352960
11.

Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study.

Kopec JA, Goel V, Bunting PS, Neuman J, Sayre EC, Warde P, Levers P, Fleshner N.

J Urol. 2005 Aug;174(2):495-9; discussion 499.

PMID:
16006879
12.

A reliable coding system to define screening prostate-specific antigen tests was developed in a case-control study.

Bunting PS, Neuman J, Goel V, Fleshner N, Kopec J, Levers P, Warde P.

J Clin Epidemiol. 2005 Jun;58(6):639-44.

PMID:
15878478
13.
14.

Laboratory survey of prostate-specific antigen testing in Ontario updated.

Bunting PS.

Clin Biochem. 2004 May;37(5):418-21. No abstract available.

PMID:
15087260
15.

Effect of a controlled feedback intervention on laboratory test ordering by community physicians.

Bunting PS, Van Walraven C.

Clin Chem. 2004 Feb;50(2):321-6. Epub 2003 Dec 18.

16.

Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation.

Bunting PS, DeBoer G, Choo R, Danjoux C, Klotz L, Fleshner N.

Clin Biochem. 2002 Sep;35(6):471-5.

PMID:
12413608
17.

Screening for prostate cancer with prostate-specific antigen: beware the biases.

Bunting PS.

Clin Chim Acta. 2002 Jan;315(1-2):71-97. Review.

PMID:
11728412
18.

Survey of community-based ontario physicians about laboratory utilization.

Bunting PS.

Clin Biochem. 2000 Mar;33(2):139-42. No abstract available.

PMID:
10751592
19.
20.
21.

Prostate-specific antigen utilization in Ontario: extent of testing in patients with and without cancer.

Bunting PS, Chong N, Holowaty EJ, Goel V.

Clin Biochem. 1998 Aug;31(6):501-11.

PMID:
9740973
22.

Percent free prostate-specific antigen after radiotherapy for prostate cancer.

Crook JM, Bunting PS.

Urology. 1998 Jul;52(1):100-5.

PMID:
9671878
23.

Laboratory survey of prostate specific antigen testing in Ontario.

Bunting PS, Miyazaki JH, Goel V.

Clin Biochem. 1998 Feb;31(1):47-9. No abstract available.

PMID:
9559224
24.

Postdoctoral training in clinical chemistry: laboratory training aspects.

Allen LC, Bunting PS.

Clin Biochem. 1995 Oct;28(5):481-97.

PMID:
8582047
25.

A guide to the interpretation of serum prostate specific antigen levels.

Bunting PS.

Clin Biochem. 1995 Jun;28(3):221-41. Review.

PMID:
7554241
26.

Acceleration of experimental lapine osteoarthritis by calcium pyrophosphate microcrystalline synovitis.

Fam AG, Morava-Protzner I, Purcell C, Young BD, Bunting PS, Lewis AJ.

Arthritis Rheum. 1995 Feb;38(2):201-10.

PMID:
7848310
27.

Education in clinical biochemistry: the Canadian scene.

Bunting PS, Goldberg DM.

Clin Chim Acta. 1994 Dec 31;232(1-2):63-84.

PMID:
7720281
28.

Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers.

Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS.

Int J Cancer. 1994 Aug 15;58(4):480-7.

PMID:
8056443
29.

Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer.

Moore MJ, Erlichman C, Thiessen JJ, Bunting PS, Hardy R, Kerr I, Soldin S.

Cancer Chemother Pharmacol. 1994;33(6):472-6.

PMID:
8137456
30.

Diagnostic aspects of angiotensin converting enzyme in pulmonary sarcoidosis.

Bunting PS, Szalai JP, Katic M.

Clin Biochem. 1987 Jun;20(3):213-9.

PMID:
2820616
31.

Comparison of serum and plasma osmolalities in a surgical ICU.

Bunting PS, Reid SR, Ngan M.

Crit Care Med. 1986 Jul;14(7):650. No abstract available.

PMID:
3720316
32.

Does serum angiotensin converting enzyme reflect intensity of alveolitis in sarcoidosis?

Cohen RD, Bunting PS, Meindok HO, Chamberlain DW, Rebuck AS.

Thorax. 1985 Jul;40(7):497-500.

33.
34.

The use of duplicates to study the effect of EDTA on the storage stability of creatine kinase.

Bunting PS, Ezer SC, Caplan BU.

Clin Chim Acta. 1981 Aug 10;114(2-3):291-5. No abstract available.

PMID:
6793272
35.

The kinetics of immobilized enzyme systems.

Laidler KJ, Bunting PS.

Methods Enzymol. 1980;64:227-48. No abstract available.

PMID:
6768959
36.
37.

Non-covalent interactions between heavy and light chains of immunoglobulin G: role of light chain variable-region subgroup.

Bunting PS, Kells DI, Kortan C, Dorrington KJ.

Immunochemistry. 1977 Jan;14(1):45-52. No abstract available.

PMID:
403128
38.

A flow method for determination of the kinetic parameters for immobilized enzymes.

Ngo TT, Bunting PS, Laidler KJ.

Can J Biochem. 1975 Jan;53(1):11-4.

PMID:
1168088
39.

Flow kinetics of L-asparaginase attached to nylon tubing.

Bunting PS, Laidler KJ.

Biotechnol Bioeng. 1974 Jan;16(1):119-34. No abstract available.

PMID:
4813161
40.

Some properties alpha-chymotrypsin and beta-galactosidase supported in polyacrylamide gels.

Bunting PS, Laidler KJ.

Can J Biochem. 1973 Dec;51(12):1598-603. No abstract available.

PMID:
4590555
41.

Kinetic studies on solid-supported -galactosidase.

Bunting PS, Laidler KJ.

Biochemistry. 1972 Nov 21;11(24):4477-83. No abstract available.

PMID:
4569280

Supplemental Content

Loading ...
Support Center